A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer

Current Opinion in Pharmacology

Volumn 29, Issue , 2016, Pages 90-96

  Hatfield, Stephen M ^a   Sitkovsky, Michail ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 5' NUCLEOTIDASE; ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; CD39 ANTIGEN; DURVALUMAB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ISTRADEFYLLINE; MEDI 9447; PRELADENANT; UNCLASSIFIED DRUG; ADENOSINE;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CELL PROTECTION; DRUG APPROVAL; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; INTRACELLULAR SIGNALING; MALIGNANT NEOPLASTIC DISEASE; NATURAL KILLER CELL; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TRIPLE NEGATIVE BREAST CANCER; TUMOR IMMUNITY; ANIMAL; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

ADENOSINE; ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNE TOLERANCE; IMMUNOTHERAPY; KILLER CELLS, NATURAL; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84978209208     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2016.06.009     Document Type: Review

References (54)

1. 1 Yang, J.C., Rosenberg, S.A., Adoptive T-cell therapy for cancer. Adv Immunol 130 (2016), 279–294.
2. 2• Hasko, G., Cronstein, B., Regulation of inflammation by adenosine. Front Immunol, 4, 2013, 85 This is important overview of the major findings in the field of inflammatory tissue damage in studies of adenosine receptors.
3. 3 Koshiba, M., Kojima, H., Huang, S., Apasov, S., Sitkovsky, M.V., Memory of extracellular adenosine A2A purinergic receptor-mediated signaling in murine T cells. J Biol Chem 272 (1997), 25881–25889.
4. 4 Armstrong, J.M., Chen, J.F., Schwarzschild, M.A., Apasov, S., Smith, P.T., Caldwell, C., Chen, P., Figler, H., Sullivan, G., Fink, S., et al. Gene dose effect reveals no Gs-coupled A2A adenosine receptor reserve in murine T-lymphocytes: studies of cells from A2A-receptor-gene-deficient mice. Biochem J 354 (2001), 123–130.
5. 5 Ohta, A., Sitkovsky, M., Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414 (2001), 916–920.
6. 6 Lukashev, D., Ohta, A., Apasov, S., Chen, J.F., Sitkovsky, M., Cutting edge: physiologic attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor in vivo. J Immunol 173 (2004), 21–24.
7. 7 Kojima, H., Gu, H., Nomura, S., Caldwell, C.C., Kobata, T., Carmeliet, P., Semenza, G.L., Sitkovsky, M.V., Abnormal B lymphocyte development and autoimmunity in hypoxia-inducible factor 1alpha-deficient chimeric mice. Proc Natl Acad Sci U S A 99 (2002), 2170–2174.
8. 8• Hatfield, S.M., Kjaergaard, J., Lukashev, D., Schreiber, T.H., Belikoff, B., Abbott, R., Sethumadhavan, S., Philbrook, P., Ko, K., Cannici, R., et al. Immunological mechanisms of the anti-tumor effects of supplemental oxygenation. Sci Transl Med, 7, 2015, 277 This is a paradigm shifting set of observations that offer promising future direction in improving the immunotherapies of cancer by supplemental oxygenation.
9. 9 Ohta, A., Gorelik, E., Prasad, S.J., Ronchese, F., Lukashev, D., Wong, M.K., Huang, X., Caldwell, S., Liu, K., Smith, P., et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A 103 (2006), 13132–13137.
10. 10 Sitkovsky, M.V., Lukashev, D., Apasov, S., Kojima, H., Koshiba, M., Caldwell, C., Ohta, A., Thiel, M., Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 22 (2004), 657–682.
11. 11 Sitkovsky, M.V., T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response. Trends Immunol 30 (2009), 102–108.
12. 12 Sitkovsky, M.V., Hatfield, S., Abbott, R., Belikoff, B., Lukashev, D., Ohta, A., Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists. Cancer Immunol Res 2 (2014), 598–605.
13. 13 Zarek, P.E., Huang, C.T., Lutz, E.R., Kowalski, J., Horton, M.R., Linden, J., Drake, C.G., Powell, J.D., A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 111 (2008), 251–259.
14. 14 Waickman, A.T., Alme, A., Senaldi, L., Zarek, P.E., Horton, M., Powell, J.D., Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor. Cancer Immunol Immunother 61 (2012), 917–926.
15. 15 Stagg, J., Divisekera, U., McLaughlin, N., Sharkey, J., Pommey, S., Denoyer, D., Dwyer, K.M., Smyth, M.J., Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A 107 (2010), 1547–1552.
16. 16 Jin, D., Fan, J., Wang, L., Thompson, L.F., Liu, A., Daniel, B.J., Shin, T., Curiel, T.J., Zhang, B., CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res, 2010.
17. 17 Kunzli, B.M., Bernlochner, M.I., Rath, S., Kaser, S., Csizmadia, E., Enjyoji, K., Cowan, P., d'Apice, A., Dwyer, K., Rosenberg, R., et al. Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer. Purinergic Signal 7 (2011), 231–241.
18. 18 Feng, L., Sun, X., Csizmadia, E., Han, L., Bian, S., Murakami, T., Wang, X., Robson, S.C., Wu, Y., Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate. Neoplasia 13 (2011), 206–216.
19. 19 Young, A., Mittal, D., Stagg, J., Smyth, M.J., Targeting cancer-derived adenosine: new therapeutic approaches. Cancer Discov 4 (2014), 879–888.
20. 20 Hellstrom, I., Hellstrom, K.E., Pierce, G.E., Yang, J.P., Cellular and humoral immunity to different types of human neoplasms. Nature 220 (1968), 1352–1354.
21. 21 Sitkovsky, M.V., Use of the A(2A) adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. Biochem Pharmacol 65 (2003), 493–501.
22. 22 Takayama, H., Trenn, G., Sitkovsky, M.V., Locus of inhibitory action of cAMP-dependent protein kinase in the antigen-receptor triggered cytotoxic T-lymphocyte activation pathway. J Biol Chem 263 (1988), 2330–2336.
23. 23 Sitkovsky, M.V., Trenn, G., Takayama, H., Cyclic AMP-dependent protein kinase as a part of the possible down-regulating pathway in the antigen receptor-regulated cytotoxic T lymphocyte conjugate formation and granule exocytosis. Ann N Y Acad Sci 532 (1988), 350–358.
24. 24 Takayama, H., Sitkovsky, M.V., Potential use of an antagonist of cAMP-dependent protein kinase to block inhibition and modulate T-cell receptor-triggered activation of cytotoxic T-lymphocytes. J Pharm Sci 78 (1989), 8–10.
25. 25 Neary, C.L., Nesterova, M., Cho, Y.S., Cheadle, C., Becker, K.G., Cho-Chung, Y.S., Protein kinase A isozyme switching: eliciting differential cAMP signaling and tumor reversion. Oncogene 23 (2004), 8847–8856.
26. 26 Klotz, K.N., Kachler, S., Inhibitors of membranous adenylyl cyclases with affinity for adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol 389 (2016), 349–352.
27. 27 Koshiba, M., Kojima, H., Huang, S., Apasov, S., Sitkovsky, M.V., Memory of extracellular adenosine/A2a purinergic receptor-mediated signalling in murine T cells. J Biol Chem 272 (1997), 25881–25889.
28. 28 Williams, B.A., Manzer, A., Blay, J., Hoskin, D.W., Adenosine acts through a novel extracellular receptor to inhibit granule exocytosis by natural killer cells. Biochem Biophys Res Commun 231 (1997), 264–269.
29. 29 Hoskin, D.W., Butler, J.J., Drapeau, D., Haeryfar, S.M., Blay, J., Adenosine acts through an A3 receptor to prevent the induction of murine anti-CD3-activated killer T cells. Int J Cancer 99 (2002), 386–395.
30. 30• Beavis, P.A., Divisekera, U., Paget, C., Chow, M.T., John, L.B., Devaud, C., Dwyer, K., Stagg, J., Smyth, M.J., Darcy, P.K., Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc Natl Acad Sci U S A 110 (2013), 14711–14716 This paper was critical in extending the evidence for the promise of A2AR antagonists in therapies of cancer.
31. 31 Mittal, D., Young, A., Stannard, K., Yong, M., Teng, M.W., Allard, B., Stagg, J., Smyth, M.J., Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res 74 (2014), 3652–3658.
32. 32•• Loi, S., Pommey, S., Haibe-Kains, B., Beavis, P.A., Darcy, P.K., Smyth, M.J., Stagg, J., CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A 110 (2013), 11091–11096 This paradigm shifting set of observations introduces the expression of adenosine generating ecto-enzymes as a poor prognosis factor and further justifies combination of anti-hypoxia-adenosinergic drugs with chemotherapies and immunotherapies of cancer.
33. 33 Whiteside, T.L., Jackson, E.K., Adenosine and prostaglandin e2 production by human inducible regulatory T cells in health and disease. Front Immunol, 4, 2013, 212.
34. 34 Schuler, P.J., Saze, Z., Hong, C.S., Muller, L., Gillespie, D.G., Cheng, D., Harasymczuk, M., Mandapathil, M., Lang, S., Jackson, E.K., et al. Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells. Clin Exp Immunol 177 (2014), 531–543.
35. 35 Fredholm, B.B., Ap, I.J., Jacobson, K.A., Linden, J., Muller, C.E., International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors–an update. Pharmacol Rev 63 (2011), 1–34.
36. 36 Young, A., Mittal, D., Stannard, K., Yong, M., Teng, M.W., Allard, B., Stagg, J., Smyth, M.J., Co-blockade of immune checkpoints and adenosine A receptor suppresses metastasis. Oncoimmunology, 3, 2014, e958952.
37. 37 Muller, C.E., Jacobson, K.A., Xanthines as adenosine receptor antagonists. Handb Exp Pharmacol, 2011, 151–199.
38. 38 Chen, J.F., Eltzschig, H.K., Fredholm, B.B., Adenosine receptors as drug targets — what are the challenges?. Nat Rev Drug Discov 12 (2013), 265–286.
39. 39 Thomas, R., Lee, J., Chevalier, V., Sadler, S., Selesniemi, K., Hatfield, S., Sitkovsky, M., Ondrechen, M.J., Jones, G.B., Design and evaluation of xanthine based adenosine receptor antagonists: potential hypoxia targeted immunotherapies. Bioorg Med Chem 21 (2013), 7453–7464.
40. 40 Ohta, A., Sitkovsky, M., Caveats in promising therapeutic targeting of the anti-inflammatory A2 adenosine receptors: the notes of caution. Commentary/opinion. Nat Rev Drug Discov, 2006, 10.1038/nrd1983-C1.
41. 41 Yang, D., Zhang, Y., Nguyen, H.G., Koupenova, M., Chauhan, A.K., Makitalo, M., Jones, M.R., St Hilaire, C., Seldin, D.C., Toselli, P., et al. The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. J Clin Invest 116 (2006), 1913–1923.
42. 42 Lu, T., Ramakrishnan, R., Altiok, S., Youn, J.I., Cheng, P., Celis, E., Pisarev, V., Sherman, S., Sporn, M.B., Gabrilovich, D., Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest 121 (2011), 4015–4029.
43. 43• Marvel, D., Gabrilovich, D.I., Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest 125 (2015), 3356–3364 This authoritative opinion by creators of this field point to the yet to be fully uncovered important influences of these cells.
44. 44 Sorrentino, R., Pinto, A., Morello, S., The adenosinergic system in cancer: key therapeutic target. Oncoimmunology, 2, 2013, e22448.
45. 45 Iannone, R., Miele, L., Maiolino, P., Pinto, A., Morello, S., Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma. Neoplasia 15 (2013), 1400–1409.
46. 46 Ryzhov, S., Novitskiy, S.V., Zaynagetdinov, R., Goldstein, A.E., Carbone, D.P., Biaggioni, I., Dikov, M.M., Feoktistov, I., Host A(2B) adenosine receptors promote carcinoma growth. Neoplasia 10 (2008), 987–995.
47. 47 Eltzschig, H.K., Sitkovsky, M.V., Robson, S.C., Purinergic signaling during inflammation. N Engl J Med, 368, 2013, 1260.
48. 48• Allard, B., Pommey, S., Smyth, M.J., Stagg, J., Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res 19 (2013), 5626–5635 Authors provide the rationale for current clinical trials to combine these two antibody treatments with drugs that inhibit adenosine-A2AR axis.
49. 49 Stagg, J., Beavis, P.A., Divisekera, U., Liu, M.C., Moller, A., Darcy, P.K., Smyth, M.J., CD73-deficient mice are resistant to carcinogenesis. Cancer Res 72 (2012), 2190–2196.
50. 50 Stagg, J., Divisekera, U., Duret, H., Sparwasser, T., Teng, M.W., Darcy, P.K., Smyth, M.J., CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res 71 (2011), 2892–2900.
51. 51 Qin, L., Thompson, L.F., Kuzel, T.M., Zhang, B., Requirement of NK cells for selective A2A receptor blockade to suppress CD73+ tumor metastasis. Immunotherapy 6 (2014), 19–21.
52. 52 Freundlieb, M., Zimmermann, H., Muller, C.E., A new, sensitive ecto-5′-nucleotidase assay for compound screening. Anal Biochem 446 (2014), 53–58.
53. 53 Zhang, B., Song, B., Wang, X., Chang, X.S., Pang, T., Zhang, X., Yin, K., Fang, G.E., The expression and clinical significance of CD73 molecule in human rectal adenocarcinoma. Tumour Biol 36 (2015), 5459–5466.
54. 54 Cekic, C., Day, Y.J., Sag, D., Linden, J., Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. Cancer Res 74 (2014), 7250–7259.